Eisai CEO Naito
Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.
- Product Code
- ILEA001501491
- Registered date
- 2023/7/07 00:00:00
- Credit
- Kyodo / Kyodo News Images
- Media source
- 2023 Kyodo News
- Media size
- 3696 × 2806 pixel
- Deployment size
- 468.43(KB)*
*File size when opened in Photoshop, etc.